Cellceutix to Present at Biotech Showcase 2017; Brilacidin for Oral Mucositis Nears Interim Results

BEVERLY, MA – Jan. 4, 2017 (GLOBE NEWSWIRE) Cellceutix Corporation, (OTCQB: CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, today announces that the Company will be presenting a corporate overview at the Biotech Showcase 2017 Investor and Networking Conference. The event is being held January 9-11, 2017, in San Francisco, CA, at the Hilton San Francisco Union Square.

Cellceutix is scheduled to present at:

Date: Monday, January 9, 2017
Time: 8:30 AM
Track: Room 2 (Ballroom Level)

The presentation will be made available online under the Events and Presentations section of Cellceutix.com at the time of the live presentation at:

Phase 2 Trial for Brilacidin-Oral Mucositis (OM)

In advance of interim data collection and analyses planned for 1Q2017 to early 2Q2017 for the ongoing Phase 2 trial for Brilacidin-OM, Cellceutix would like to provide additional insight into this mid-phase study.

Brilacidin-OM represents a potential significant treatment breakthrough, as there are currently no preventative drugs approved for Oral Mucositis for solid tumors. Limited existing therapies focus on temporarily ameliorating symptoms.  Cellceutix’s goal is to show that Brilacidin-OM has dual functionality in not only shortening the duration and severity of OM, but also preventing the onset of the condition, something no other drug developer has been able to achieve.

Should Brilacidin emerge as the first, preventative, FDA-approved treatment for OM, we anticipate its wide adoption among health care professionals. Insurers and governmental programs, such as Medicare and Medicaid, should appreciate the potential for cost savings that the treatment might provide. An estimated $17,000-$25,000 in added inpatient costs, per case, associated with managing OM could be substantially reduced, if not eliminated altogether.

An estimated 400,000 patients in the United States suffer from Oral Mucositis, a painful and debilitating side effect of cancer treatments.


Sign-up for Cellceutix email alerts is available at:

About Oral Mucositis
Oral Mucositis (OM) is a frequent, painful and debilitating complication of chemoradiation commonly manifesting in the treatment of head and neck tumors. Characterized by inflammation and ulceration, patients suffering from OM are often unable to speak or eat (requiring the insertion of a feeding tube) and more susceptible to bacterial infections, with severe cases leading to hospitalization, with increased treatment costs of up to $25,000. Affecting over 400,000 people in the United States, there currently are no approved medications for the prevention of OM in this population, with only limited palliative care options available. Worldwide, the potential market for OM is expected to exceed $1 billion in the next few years.